TLDRocket
Sign in

OpenAI acquired Orchestra Bio to expand its AI life-sciences and biopharma R&D efforts

Acquisition Provisional 90% confidence first seen

OpenAI announced the acquisition of Orchestra Bio, an AI software startup focused on supporting life-sciences R&D for biopharma drug development. OpenAI said it will integrate Orchestra Bio’s team and technology into its Rosalind model and Rosalind Workbench to help plan experiments and analyze results, and to extend Rosalind’s use with biotech customers such as Moderna and Novo Nordisk.

OpenAI Orchestra Bio Moderna Novo Nordisk Rosalind Rosalind Workbench

The deal

Orchestra Bio Undisclosed Acquisition · announced 20 Oct 2026

Investors OpenAI

Deal terms as reported in the coverage below.

Source coverage

OpenAI acquires Orchestra Bio OpenAI official OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business TechCrunch independent

The daily briefing

Every AI story that matters, in your inbox by 8am.

TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.